Compounders Research Compare

NeuroSense Therapeutics Ltd.(NRSN)

Biotechnology · Herzliya, TA

$4.07+0.04 (+0.99%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Herzliya, TA

17 employees

www.neurosense-tx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alon Ben-Noon

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T22:52:06.770Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:52:06.770Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 7,193,688
Total debt · period ending 2025-12-31: 170,000
Cash · period ending 2025-12-31: 166,000
TTM operating income · period ending 2025-12-31: -11,085,000

FMP input reference: 7269c43ec051f04bc9b25698fa87f96476c1bd81d443a59abbb4ab2a9593cf8e

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NRSN EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

NRSN Competitors' EV/EBIT Ratio

NeuroSense Therapeutics Ltd.

Current

Market Cap

$7.19M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Co-Diagnostics, Inc.

Market Cap

$7.19M

EV/EBIT Ratio

N/A

TTM Avg

1.45x

3Y Avg

7.74x

5Y Avg

7.74x

Longeveron Inc.

Market Cap

$7.15M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Skye Bioscience, Inc.

Market Cap

$7.12M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InMed Pharmaceuticals Inc.

Market Cap

$7.31M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curanex Pharmaceuticals Inc Common Stock

Market Cap

$7.07M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA BIO, Inc.

Market Cap

$7.04M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Quince Therapeutics, Inc.

Market Cap

$7.46M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Exicure, Inc.

Market Cap

$6.88M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mangoceuticals, Inc.

Market Cap

$7.64M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
NeuroSense Therapeutics Ltd. (NRSN)	$7.19M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$7.19M	N/A	1.45x	7.74x	7.74x
Longeveron Inc. (LGVN)vs ›	$7.15M	N/A	N/A	N/A	N/A
Skye Bioscience, Inc. (SKYE)vs ›	$7.12M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.31M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.07M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.04M	N/A	N/A	N/A	N/A
Quince Therapeutics, Inc. (QNCX)vs ›	$7.46M	N/A	N/A	N/A	N/A
Exicure, Inc. (XCUR)vs ›	$6.88M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.64M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics